Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InMed Pharmaceuticals Inc.INM · Entity 8139 | Director | December 20, 2024 | December 23, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InMed Pharmaceuticals Inc.
Report date December 20, 2024 · Filed December 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2029-12-19 | Direct | 975 |
Reported balance
After 2024-12-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-20 · Grant · Acquired 550 · Balance 975 F1: The options were granted on 12/20/2024 and will vest 100% on the one-year anniversary of the grant date (December 19, 2025) or immediately prior to the next Annual General Meeting, whichever is sooner. F2: On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on 12/20/2024 and will vest 100% on the one-year anniversary of the grant date (December 19, 2025) or immediately prior to the next Annual General Meeting, whichever is sooner.
F2: On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2024 Filed Dec 23, 2024 09:22 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 550 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001213900-24-111558 · ownership.xml · derivative · entry 1 Grove Janet P · CIK 0001355675 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 975 Underlying: Common shares · 550 shares Expires 2029-12-19 F1 · derivative.exercise_date: The options were granted on 12/20/2024 and will vest 100% on the one-year anniversary of the grant date (December 19, 2025) or immediately prior to the next Annual General Meeting, whichever is sooner. F2 · balance_after: On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split. Read SEC document |
| December 23, 2023 Filed Dec 26, 2023 13:08 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,100 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001213900-23-098491 · ownership.xml · derivative · entry 1 Grove Janet P · CIK 0001355675 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common shares · 7,100 shares Expires 2028-12-22 F1 · derivative.exercise_date: The options were granted on 12/23/2023 and will vest 100% on the one-year anniversary of the grant date (December 23, 2024) or immediately prior to the next Annual General Meeting, whichever is sooner. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 16:54 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 840 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001213900-22-080969 · ownership.xml · derivative · entry 1 Grove Janet P · CIK 0001355675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common shares · 840 shares Expires 2027-12-15 F1 · derivative.exercise_date: The options were granted on 12/16/2022 and will vest as follows: Vesting 100% on the one-year anniversary of the grant date (Dec 16, 2023) or immediately prior to the next AGM, whichever is sooner. F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 20:16 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001213900-22-008775 · ownership.xml · derivative · entry 1 Grove Janet P · CIK 0001355675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common shares · 14,000 shares Expires 2027-02-17 F1 · derivative.exercise_date: The options were granted on 02/18/2022 with 390 stock options vesting on the 18th day of each of the 35 months commencing March 18, 2022 through January 18, 2025 and 350 stock options will vest on February 18, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.